1
|
St-Laurent MP, Singh P, McConkey DJ, Lucia MS, Koshkin VS, Stratton KL, Bivalacqua TJ, Kassouf W, Porten SP, Bangs R, Plets M, Thompson IM, Meeks JJ, Caruso VM, Ward CT, Mazzarella BC, Phillips KG, Bicocca VT, Levin TG, Lerner SP, Black PC. Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer. Eur Urol 2025:S0302-2838(25)00217-9. [PMID: 40404526 DOI: 10.1016/j.eururo.2025.03.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2024] [Revised: 02/27/2025] [Accepted: 03/27/2025] [Indexed: 05/24/2025]
Abstract
As new treatments for bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) emerge, better methods are needed to guide therapeutic decisions. This study analyzed urine tumor DNA (utDNA) from patients treated with atezolizumab in the SWOG S1605 trial to determine whether utDNA profiling can stratify the risk of treatment failure. Urine samples were analyzed using the UroAmp assay at baseline and 3 mo from 89 and 77 patients, respectively. Only 13% of UroAmp-positive patients at baseline achieved a complete response at 6 mo compared with 71% of UroAmp-negative patients (p < 0.001). The 18-mo event-free survival (EFS) was significantly lower for UroAmp-positive patients at baseline (23%) than for UroAmp-negative patients (51%; hazard ratio [HR] 2.8, p < 0.001). Among patients with no clinical evidence of disease at 3 mo (n = 51), the 18-mo EFS was 38% for UroAmp-positive and 86% for UroAmp-negative (HR 3.5, p = 0.01) patients. These findings suggest that utDNA profiling at baseline and after 3 mo of treatment can help identify patients with BCG-unresponsive NMIBC who are less likely to benefit from systemic immunotherapy.
Collapse
Affiliation(s)
| | | | - David J McConkey
- Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA
| | | | - Vadim S Koshkin
- University of California San Francisco, Helen Diller Family Cancer Center, San Francisco, CA, USA
| | | | | | | | - Sima P Porten
- University of California San Francisco, Helen Diller Family Cancer Center, San Francisco, CA, USA
| | - Rick Bangs
- Bladder Cancer Advocacy Network, Pittsford, NY, USA
| | - Melissa Plets
- SWOG Statistics and Data Management Center, Seattle, WA, USA
| | - Ian M Thompson
- University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
| | - Joshua J Meeks
- Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
| | - Vincent M Caruso
- Convergent Genomics, Research and Development, San Francisco, CA, USA
| | - Ceressa T Ward
- Convergent Genomics, Research and Development, San Francisco, CA, USA
| | | | - Kevin G Phillips
- Convergent Genomics, Research and Development, San Francisco, CA, USA
| | - Vincent T Bicocca
- Convergent Genomics, Research and Development, San Francisco, CA, USA
| | - Trevor G Levin
- Convergent Genomics, Research and Development, San Francisco, CA, USA
| | - Seth P Lerner
- Baylor College of Medicine, Dan L Duncan Cancer Center, Houston, TX, USA
| | - Peter C Black
- University of British Columbia, Vancouver, BC, Canada.
| |
Collapse
|
2
|
Subiela JD, Scilipoti P, Contieri R, Lobo N, Pichler R, Kamat AM. Management Dilemma for Very High-risk Non-muscle-invasive Bladder Cancer: Real-World Data Challenge the Guideline Recommendation for Upfront Radical Cystectomy. Eur Urol 2025:S0302-2838(25)00283-0. [PMID: 40374480 DOI: 10.1016/j.eururo.2025.05.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2025] [Revised: 04/20/2025] [Accepted: 05/04/2025] [Indexed: 05/17/2025]
Abstract
We discuss real-world evidence that challenges the guideline recommendation of upfront radical cystectomy for all patients with very high-risk non-muscle-invasive bladder cancer. The evidence highlights the need for more accurate and dynamic tools to guide clinical decision-making. Until these are available, treatment decisions should be individualized and made in close consultation with the patient.
Collapse
Affiliation(s)
- José Daniel Subiela
- Department of Urology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Universidad de Alcala, Madrid, Spain.
| | - Pietro Scilipoti
- Division of Experimental Oncology, Department of Urology, Urological Research Institute, Vita-Salute San Raffaele University, Milan, Italy
| | - Roberto Contieri
- Department of Urology, Istituto Nazionale Tumori di Napoli IRCCS, Fondazione G. Pascale, Naples, Italy
| | - Nijati Lobo
- Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Renate Pichler
- Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria
| | - Ashish M Kamat
- Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| |
Collapse
|
3
|
Steinmetz AR, Jazayeri B, Pierce M, Mokkapati S, McConkey D, Li R, Dinney CP. Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancer. Expert Opin Biol Ther 2025; 25:149-159. [PMID: 39779686 DOI: 10.1080/14712598.2024.2445674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2024] [Accepted: 12/18/2024] [Indexed: 01/11/2025]
Abstract
INTRODUCTION Approximately 75% of bladder cancer cases are non-muscle invasive at diagnosis. Drug development for non-muscle invasive bladder cancer (NMIBC) has historically lagged behind that of other malignancies. No treatment has demonstrated the ability to overcome drug resistance that ultimately leads to recurrence and progression. Gene therapy is emerging as a promising option for patients with NMIBC. AREAS COVERED This review summarizes the clinical application of gene therapy in NMIBC management and discusses recent clinical trials involving the adenoviral vector-based treatment nadofaragene firadenovec, and the oncolytic serotype 5 adenovirus, cretostimogene grenadenorepvec. Nadofaragene received approval by the Food and Drug Administration in December 2022, and cretostimogene has been granted Fast Track Designation and Breakthrough Therapy Designation. Ongoing trials are investigating strategies to augment efficacy and durability of these therapies. EXPERT OPINION Gene therapy may overcome resistance mechanisms of other NMIBC treatments, and data suggest a role for combination therapy with additive or synergistic agents. Significant differences in trial design limit comparability of agents across trials, highlighting the need for critical assessment of published findings. While initial investigations were in high-risk patients who recur despite frontline therapy with Bacillus Calmette-Guerin (BCG), there is growing interest in BCG-naïve and intermediate-risk populations.
Collapse
Affiliation(s)
- Alexis R Steinmetz
- Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Behzad Jazayeri
- Department of Urology, Moffitt Cancer Center, Tampa, FL, USA
| | - Morgan Pierce
- Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Sharada Mokkapati
- Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - David McConkey
- Brady Urological Institute, Johns Hopkins Greenberg Bladder Cancer Institute, Johns Hopkins University, Baltimore, MD, USA
| | - Roger Li
- Department of Urology, Moffitt Cancer Center, Tampa, FL, USA
| | - Colin P Dinney
- Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| |
Collapse
|